MGMT and neoplasm: After treatment with temozolomide on either standard dose (schedule A, 200 mg m−2 for 5 days) or dose-intense (schedule B, 100 mg m−2 for 21 days) schedules, MGMT activity in tumour was maximally depleted within 3–6 days after initiation of therapy.